Fundraising Fox
/People
Sign in

Rahul Ballal

Executive at Mediar Therapeutics

Boston, Massachusetts, United States

Kauffman Fellow · Class 15

Find your path to Rahul

1,449 people in our graph share verified history with Rahul — schools, employers, funds. One of them is your warm intro.

Richard HeymanunlockedRahul: together at Enliven Therapeutics (2023–2026)
Rahul: together at Enliven Therapeutics
Rahul: together at Agios Pharmaceuticals
×9Rahul: together at Versant Ventures

About

Rahul Ballal is the Chief Executive Officer of Mediar Therapeutics, with over 15 years of experience in company building, business development, and financing. He previously led Imara (NASDAQ: IMRA) as president and CEO from Series A through its IPO and subsequent merger with Enliven Therapeutics, and earlier held roles at Northern Biologics, Versant Ventures, Flexion Therapeutics, and ASM Ventures. He serves on the boards of Enliven Therapeutics, Agios Pharmaceuticals, InduPro, and Vaderis Therapeutics AG, and holds a Ph.D. in biochemistry from Georgetown University, an MS in bioinformatics from Johns Hopkins University, and a BS in biology from Brown University.

Executive at Mediar Therapeutics

Intro paths

→

In turn, Rahul can intro founders to Mediar Therapeutics's investors below.

Mediar Therapeutics's investors · 11

Agent CapitalWalthamAmplitude Venture CapitalMontreal · since 2026GimvAntwerp · $20M – $400M checksLongwood FundBoston · since 2026Mission BiocapitalSan Francisco · $500K checks · since 2025Novartis Venture FundBasel · $5M – $25M checks · since 2022Ono Venture Investment, Inc.South San FranciscoPfizer Venture Investments$5M – $20M checksPfizer VenturesShangBay Capital LLCPalo AltoSofinnova PartnersParis · $540K – $27M checks · since 2025

Experience

  1. Mediar TherapeuticsCEOcurrent2023 — presentBoston, MA
  2. Enliven TherapeuticsBoard Member (NASDAQ: ELVN)current2023 — presentBoston, MA
  3. Agios PharmaceuticalsBoard Member (NASDAQ: AGIO)current2022 — presentCambridge, MA
  4. Vaderis Therapeutics AGBoard Membercurrent2022 — presentBoston, MA
  5. InduProBoard Membercurrent2024 — presentSeattle, Washington, United States
  6. The Park School - Brookline, MATrustee & Secretary of Corporation2019 — 2026Brookline, MA
  7. Imara, IncCEO (NASDAQ: IMRA)2018 — 2023Greater Boston Area
  8. Versant VenturesEntrepreneur in Residence & CBO @ Northern Biologics2016 — 2018Boston MA
  9. Flexion TherapeuticsVice President of Business Development2011 — 2016Woburn, MA
  10. Novartis Venture FundsKauffman Fellow (Class 15)2010 — 2012
  11. Broad InstituteBusiness Development Manager2009 — 2011
  12. RedmindCEO/Founder2000 — 2005

Skills & more

OncologyBiochemistryVaccinesBiotechnologyVenture CapitalStart-upsLifesciencesEntrepreneurshipPharmaceutical Industry

From Rahul's professional profile.

Frequently asked questions

Who is Rahul Ballal?
Rahul Ballal is the Chief Executive Officer of Mediar Therapeutics, with over 15 years of experience in company building, business development, and financing. He previously led Imara (NASDAQ: IMRA) as president and CEO from Series A through its IPO and subsequent merger with Enliven Therapeutics, and earlier held roles at Northern Biologics, Versant Ventures, Flexion Therapeutics, and ASM Ventures. He serves on the boards of Enliven Therapeutics, Agios Pharmaceuticals, InduPro, and Vaderis Therapeutics AG, and holds a Ph.D. in biochemistry from Georgetown University, an MS in bioinformatics from Johns Hopkins University, and a BS in biology from Brown University.
Where does Rahul Ballal work?
Rahul Ballal is Executive at Mediar Therapeutics.
Where did Rahul Ballal go to school?
Rahul Ballal studied at Georgetown University School of Medicine (Doctor of Philosophy (Ph.D.), Biochemistry and Molecular Biology); The Johns Hopkins University (MS, Bioinformatics); Brown University (BS, Biology).

Founder mafias

Same school

Shared employers